MedPath

Evaluating the Effect of Inositol Supplementation in Overweight Children on Basal Insulin and Body Weight

Not Applicable
Conditions
Insulin Resistance
Interventions
Other: Placebo
Dietary Supplement: Inofolic Combi
Registration Number
NCT03920787
Lead Sponsor
Alice Andreassi
Brief Summary

Inositol in involved in the insulin pathway. In literature it has been demonstrated to improve insulin sensitivity and ovarian function in women affected by PCOS.

In a preliminary study conducted on obese children between 7 and 15 years, the investigators have demonstrated that Inositol administration (Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg) before a Glucose Oral Tolerance Test reduces the increase of insulin levels, particularly in subjects with basal insulin ≥ 15 uU/ml.

So the aim of this study is to evaluate the potential therapeutic effect of inositol, as non-pharmacologic agent, in preventing tipe II diabetes in children.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
23
Inclusion Criteria
  • 8-18 years old
  • overweight or obesity
  • basal insulin ≥ 20 uU/ml
Exclusion Criteria
  • pubertal delay
  • hypogonadism
  • hypothyroidism or hyperthyroidism
  • obesity-related genetic diseases

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboAdministration of placebo. 2 capsules every day for 1 month
InositolInofolic CombiAdministration of Inofolic Combi (Myo-inositol 1100 mg + D-Chiro-inositol 27,6 mg + Folic Acid 400 μg - Lo.Li Pharma S.r.l.) 2 capsules every day for 1 month
Primary Outcome Measures
NameTimeMethod
Basal Insulin1 month

Evaluation of the efficacy of inositol in reducing basal insulin

Secondary Outcome Measures
NameTimeMethod
Body weight1 month

Evaluation of the efficacy of inositol in reducing body weight

Trial Locations

Locations (1)

AO San Paolo

🇮🇹

Milan, Mi, Italy

© Copyright 2025. All Rights Reserved by MedPath